Exozymes Inc. · NASDAQ:EXOZ
Exozymes — Investor Presentation (November 2025)
18 slides from Exozymes's investor presentation, Nov 13, 2025
Slide 1: Driving Metabolic Performance
Driving Metabolic Performance NCT for Nutrition NCT Analogs for Pharma
Slide 2: eXoZymes' Safe Harbor
eXoZymes’ Safe Harbor This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, Strategies and expectations, can general
Slide 3: Business Risk & Uncertainties
Business Risk & Uncertainties Regulatory Approvals GRAS (Generally Recognized as Safe) clearance for supplements NDIN (New Dietary Ingredient Notification) for nutraceuticals IND (Investigational New Drug) pathway for pharmaceutical analogs Manufacturing & Scale-Up Technical risks in scaling cell-fr
Slide 4: Metabolic Disease, Epidemic of Our Lifetime
Metabolic Disease, Epidemic of Our Lifetime Chronic and Widespread affecting >1.4 bn people globally Obesity, Diabetes GLP-1 receptor agonists are reshaping treatment market Serving massive growing market GLP-1s Limit Intake Mimics gut hormones to suppress appetite Lean mass loss and digestion disco
Slide 5: Amplifying Metabolism
Amplifying Metabolism NCT is an agonist for HNF4a, a key metabolic regulator ——>- © FE A N-trans-Caffeoyltyramine key transcriptional regulator of metabolism Natural Molecule “Metabolic Hero” Based on pre-clinical research published by Sanford Burnham Prebys L___» Mitochondria grows mitochondria inc
Slide 6: Preclinical Support for NCT in Mouse Models
Preclinical Support for NCT in Mouse Models Less Weight Gain Without Changing Diet 130% Reduction in Weight Gain HF NCT high-fat diet and no change in food intake Veeriah, V., Lee, SH. & Levine, F. Cell Death Dis 13, 89(2022) t Mitochondrial Mass biomarkers for mitochondrial growth and fatty acid ox
Slide 7: 1. NCT Unlocked by eXoZymes
1. NCT Unlocked by eXoZymes Advantaged Cell-Free Method for Producing NCT for nutraceuticals Licensed to NCTx
Slide 8: Unlocking Scale: Solving the NCT bottleneck
Unlocking Scale: Solving the NCT bottleneck The Challenge NCT is nearly absent in nature with trace abundance O O 1 A% Existing sources are mixtures of less potent natural analogs . . wp cgt NCT found in peppercorns Conventional manufacturing approaches are cost prohibitive sii Our Solution >90% Exo
Slide 9: eXoZymes Biomanufacturing Breakthrough
eXoZymes Biomanufacturing Breakthrough Concept to Gram-Scale NCT in Only 5 Months Lab scale work created technical and economic feasibility package in record time eXezy mes Concept Jan 2025 6. (Sl POG, IP Filed Gram-scale Production May 2025 100x Scale-up a Projected Achievement Dec 2025 Sampling an
Slide 10: Comparison Against Alternative Route
Comparison Against Alternative Route Cell Free is Projected to be the Most Advantaged Path to NCT NCT Production Cost Estimates (projected at 100 T scale) Fermentation estimate based on published patent data Cell-free estimate based on eXoZymes FELO Market value estimate for NCT bulk ingredient sale
Slide 11: Scale-up Roadmap
Scale-up Roadmap Commercialization Pathway for NCT First Production Scale-up 100X 2026 Q2 Q3 Q4 Q1’27 Optimization Tech Transfer Scale-up Deliver NCT ingredient to market Scalable and economic process ready to disrupt metabolic disease market
Slide 12: Photo mock-up example of NCTx supplement product
Photo mock-up example of NCTx supplement product NCTx an eXoZymes Spinout to Address Consumer Wellness Clinically inspired Nutraceutical addressing a $200B+ Market Longevity (10%) @ Metabolic Health (12%) @ Digestive Health Consumer Top Priorities (18%) Align with NCT impact claims Mental Cognition
Slide 13: Projecting Market Demand for NCTx Spinout
Projecting Market Demand for NCTx Spinout Rate of Market Adoption depends on consumer acceptance and conversion to retail In 30 capsule bottles 2026 2027 2028 2029 2030 Pilot Production Market Launch DTC Growth Boutique Retail Regional Retail =n Sales: sampling Sales: 50-300 K bottles Sales: 1-3 M b
Slide 14: 2. NCT Analogs Unlocked by eXoZymes
2. NCT Analogs Unlocked by eXoZymes New to Nature Chemical Analogs of NCT to address pharmaceuticals Licensable to support development of an Investigational New Drug Application
Slide 15: eXoZymes NCT Analog Platform
exoZymes NCT Analog Platform Laying the Foundation to Claim Therapeutic Space \ Produce , \ Beceem Value Inflection Point Map Analogs Agri In-vitro Screen Candid Strong patent moat around natogs andidates potent drug candidates Map the landscape and Rapidly Produce via Test analog candidates Targeti
Slide 16: Transforming Mitochondrial Health
Transforming Mitochondrial Health Pharma Markets: $100B MASH, IBD & Obesity Pst [vats Fatty Liver Disease (MASH) Inflammatory Bowel Disease (IBD) Obesity 1 approved medication with modest benefit Faster healing and rejuvenation Surgery avoidance Crowded with similar GLP hormone mimics
Slide 17: Pharma's Growing Appetite for Mitochondrial Innovation
Pharma’s Growing Appetite for Mitochondrial Innovation Recent Key Acquisitions in Metabolism Akero Therapeutics acquired by Novo Nordisk October 2025 Deal Value: $5.2B Phase 3 Indication: MASH 89 Bio acquired by Roche September 2025 Deal Value: $3.5B Phase 3 Indication: MASH Inversago Pharma acquire
Slide 18: Thank you for your attention
Thankyou for your attention